Goldman Sachs’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-460,505
| Closed | -$916K | – | 6471 |
|
|
2025
Q2 | $916K | Sell |
460,505
-195,206
| -30% | -$357K | ﹤0.01% | 4770 |
|
|
2025
Q1 | $951K | Sell |
655,711
-43,638
| -6% | -$80.7K | ﹤0.01% | 4714 |
|
|
2024
Q4 | $1.45M | Buy |
699,349
+453,018
| +184% | +$851K | ﹤0.01% | 4559 |
|
|
2024
Q3 | $434K | Buy |
246,331
+204,717
| +492% | +$525K | ﹤0.01% | 5124 |
|
|
2024
Q2 | $602K | Buy |
+41,614
| New | +$572K | ﹤0.01% | 4729 |
|
|
2024
Q1 | – | Sell |
-20,314
| Closed | -$326K | – | 5696 |
|
|
2023
Q4 | $326K | Buy |
20,314
+2,952
| +17% | +$39.2K | ﹤0.01% | 4951 |
|
|
2023
Q3 | $234K | Sell |
17,362
-13,456
| -44% | -$189K | ﹤0.01% | 4984 |
|
|
2023
Q2 | $530K | Buy |
30,818
+15,853
| +106% | +$246K | ﹤0.01% | 4717 |
|
|
2023
Q1 | $247K | Sell |
14,965
-416
| -3% | -$6.66K | ﹤0.01% | 5204 |
|
|
2022
Q4 | $257K | Buy |
+15,381
| New | +$278K | ﹤0.01% | 5208 |
|
Goldman Sachs's HLVX Position: Q3 2025 in Review
Goldman Sachs sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 460,505 shares — an estimated $916K sold.
Goldman Sachs first reported a position in HLVX in Q4 2022 and held it in 10 quarters. The position peaked at $1.45M in Q4 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Goldman Sachs reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Goldman Sachs sold 460,505 HilleVax shares in Q3 2025, an estimated $916K.
- Goldman Sachs first reported a position in HilleVax in Q4 2022 and held it in 10 quarters.
- Goldman Sachs's HilleVax position peaked at $1.45M in Q4 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.